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U2 small nuclear ribonucleoprotein (snRNP) auxiliary factor 65 kDa (U2AF65) is an essential splicing factor in the
recognition of the pre-mRNA 3 splice sites during the assembly of the splicing commitment complex. We report here that
U2AF65 is proteolyzed during apoptosis. This cleavage is group I or III caspase dependent in a noncanonical single site
localized around the aspartic acid128 residue and leads to the separation of the N- and C-terminal parts of U2AF65. The
U2AF65 N-terminal fragment mainly accumulates in the nucleus within nuclear bodies (nucleoli-like pattern) and to a
much lesser extent in the cytoplasm, whereas the C-terminal fragment is found in the cytoplasm, even in localization
studies on apoptosis induction. From a functional viewpoint, the N-terminal fragment promotes Fas exon 6 skipping from
a reporter minigene, by acting as a dominant-negative version of U2AF65, whereas the C-terminal fragment has no
significant effect. The dominant-negative behavior of the U2AF65 N-terminal fragment can be reverted by U2AF35
overexpression. Interestingly, U2AF65 proteolysis in Jurkat cells on induction of early apoptosis correlates with the
down-regulation of endogenous Fas exon 6 inclusion. Thus, these results support a functional link among apoptosis
induction, U2AF65 cleavage, and the regulation of Fas alternative splicing.
INTRODUCTION
U2 small nuclear ribonucleoprotein (snRNP) auxiliary fac-
tors (U2AF65-U2AF35) cooperate in 3 splice site (3ss) rec-
ognition through direct interactions with the branch point
and the branch-binding protein SF1/BBP as well as with the
polypyrimidine tract (PT) and the conserved AG dinucle-
otide of the 3ss (Valca´rcel et al., 1996; Merendino et al., 1999;
Wu et al., 1999; Zorio and Blumenthal, 1999; Soares et al.,
2006). U2AF65 contains three RNA recognition motifs
(RRMs) and an N-terminal region rich in basic residues (RS
domain). RRMs 1 and 2 of U2AF65 display a canonical
RRM-fold, bind RNA in vitro, and are implicated in high-
affinity binding to the PT (Zamore et al., 1992; Banerjee et al.,
2003; Sickmier et al., 2006). RRM3 is a noncanonical RRM
and mediates the SF1 interaction (Selenko et al., 2003). Rec-
ognition of the PT by U2AF65 is key to splice site selection
and spliceosome assembly for the major class of introns in
higher eukaryotes. Both length and pyrimidine content of
this sequence are critical determinants of the relative
strength of competing 3ss and therefore of differential 3ss
use as a major source of proteome diversity (Reed, 1989;
Izquierdo and Valca´rcel, 2006).
Apoptosis is induced by many different stimuli, including
growth factor withdrawal, chemotherapeutic compounds,
membrane-bound death receptors, or DNA-damaging
agents (Krammer, 2000; Adams, 2003). Whatever the initial
signal, common characteristic cytological and molecular
changes occur during apoptosis (Adams, 2003). Several sig-
naling components and apoptosis pathways have been iden-
tified and elucidated at the molecular level (Adams, 2003).
When apoptosis is induced, caspases, a family of aspartyl-
specific cysteine proteases, are activated and act as effectors
of apoptosis (Earnshaw et al., 1999). The effector caspases
then selectively cleave specific target proteins, resulting in
the biochemical, morphological, and molecular features as-
sociated with imminent cell death (Earnshaw et al., 1999). An
understanding of the mechanisms of apoptosis requires the
caspase substrates to be identified and the consequences of
their proteolytic cleavage to be established. Until now,
caspases have been reported to cleave 300 different pro-
teins (Fischer et al., 2003), but, in most cases, the conse-
quences of protein cleavage are poorly understood.
The aim of this work was to examine whether U2AF65
proteolysis during apoptosis has functional consequences on
the control of Fas alternative splicing. The results show that
the N-terminal fragment down-regulates Fas exon 6 inclu-
sion. Moreover, the results suggest that alternative splicing
is modulated by U2AF65 cleavage during early apoptosis.
MATERIALS AND METHODS
Cell Cultures and Apoptosis Induction
HeLa and Jurkat cells were cultured as described previously (Izquierdo and
Valca´rcel, 2007a). Apoptosis was induced by means of the following agents:
500 ng/ml anti-Fas antibody (immunoglobulin [Ig]M clone CH11) (Millipore,
Billerica, MA), 2 M staurosporine (Sigma-Aldrich, St. Louis, MO), and 10
g/ml cycloheximide (Sigma-Aldrich). In addition, HeLa cells were irradi-
ated with UV light (100 mJ/cm2). For inhibition of caspases, cells were
preincubated for 1 h with 5 M pan-caspase inhibitor benzyloxycarbonyl-
Val-Ala-Asp (OMe) fluoromethylketone (z-VAD-fmk; BIOMOL Research
Laboratories, Plymouth Meeting, PA) before treatment with apoptotic agents.
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Plasmids
Fas minigene was described previously (Fo¨rch et al., 2000; Izquierdo et al.,
2005). The constructs containing human U2AF65 and U2AF35 cDNAs were
kindly provided by Dr. J. Valca´rcel (Centre de Regulació Genòmica, Barce-
lona, Spain). The green fluorescent protein (GFP)-U2AF65 derivative plas-
mids containing either a 128-amino acid deletion at the N terminus, a 347-
amino acid deletion at the C terminus, or directed mutagenesis from
aspartic128 to alanine were generated with Pfu Turbo DNA polymerase (Strat-
agene, La Jolla, CA). Fas I6 minigene was generated from Fas wild-type (wt)
minigene by a polymerase chain reaction (PCR)-based method as described
above. The sequence of all constructs was verified by sequencing.
Protein Analysis
Whole-cell extracts were prepared by resuspending an aliquot of untrans-
fected and transfected HeLa cells in lysis buffer (50 mM Tris-HCl, pH 8.0, 140
mM NaCl, 1.5 mM MgCl2, 0.1% Nonidet P-40 plus a cocktail of protease
inhibitors), freeze-thawing three times, and centrifuging at 10,000 rpm for 5
min. Postnuclear fractions were isolated from aliquots of HeLa cells sus-
pended in lysis buffer, incubated for 5 min at 4°C, and centrifuged at 4000 rpm
for 5 min. The supernatants were collected and stored as cytoplasmic frac-
tions. The resulting pellets were resuspended in lysis buffer, freeze-thawed
three times and centrifuged at 10,000 rpm for 5 min. The supernatants were
collected as enriched nuclear fractions. All centrifugations were carried out
in a microfuge at 4°C. The different fractions were stored at 70°C. Protein
concentration was determined with the Bradford reagent (Bio-Rad protein
assay; Bio-Rad, Hercules, CA) using bovine serum albumin as standard. For
Western blot analyses, equal amounts of protein from the fractions were
loaded on 10% SDS-PAGE and Western blots were performed using nylon
membranes and the corresponding antibodies. Immunoblots were carried out
using the following antibodies: anti-U2AF65 (MC3; provided by Dr. J. Val-
ca´rcel); anti-T cell intracellular antigen (TIA)-1 (C-20), anti-TIAR (C-18), and
anti-caspase-3 (H-277) from Santa Cruz Biotechnology (Santa Cruz, CA);
anti-polypyrimidine tract-binding protein (PTB) (BB7; provided by Dr. C. W.
Smith, University of Cambridge, United Kingdom); anti--tubulin (B-5-1-2;
Sigma-Aldrich); anti-poly(ADP-ribose) polymerase (PARP) (C-2-10; BIOMOL
Research Laboratories); and anti-GFP (JL-8; Clontech, Mountain View, CA).
HeLa extracts were analyzed for caspase-3 or caspase-3–like activity with
peptide substrate DEVD-para-nitroanilide (DEVD-p-NA) (ApoAlert caspase-3
colorimetric assay kit; Clontech). In vitro transcription and translation assays
were performed with a transcription-translation–coupled system (Promega,
Madison, WI). HeLa nuclear extracts (Dignam et al., 1983) or TIA-1b/U2AF65
translated in vitro was incubated with recombinant caspase-1–10 (Multi-
CasPak-4, Active Caspases 1-10, AK-010; BIOMOL Research Laboratories).
Immobilon INSTA-Blot membrane containing samples of several human cell
lines (HeLa, Jurkat, Daudi, 293, Rh 30, A375, T98G, HCT-116, and Hep-G2)
were obtained from Calbiochem (San Diego, CA).
Fluorescence Microscopy Analysis
HeLa cells were grown for 24 h on coverslips, and then they were washed
three times with phosphate-buffered saline (PBS), fixed in absolute methanol
at 20°C for 2 min, washed three times with PBS, and processed. For
immunofluorescence experiments, the coverslips were incubated for 1 h at
room temperature with the primary antibody diluted in PBS solution (anti-
U2AF65 MC3 antibody [dilution 1:200]). The samples were then washed three
times with PBS and incubated for 1 h with the secondary antibody (Alexa
594-coupled donkey anti-mouse IgG [dilution 1:500]) plus Hoechst 33258 (0.1
M). The samples were then washed three times in PBS and mounted with
Mowiol (Calbiochem) before fluorescence analysis. The subcellular distribu-
tion of green fluorescent protein (GFP)-tagged proteins was analyzed 24 h
after transfection, and Hoechst 33258 (0.1 M) was added to the cell medium
for 15 min before cell fixation. The microscopic observations of endogenous
U2AF65-antibody complexes, Hoechst, or GFP-fused proteins were carried
out by epifluorescence using a fluorescence microscope (DM 4000B; Leica,
Wetzlar, Germany) equipped with corresponding excitation filters. Digital
images were acquired with a Leica camera and processed with the Leica
software package.
DNA Transfections, RNA Isolation, and Reverse
Transcription (RT)-PCR Analysis
DNA transfections, total and cytoplasmic RNA isolations, and RT-PCR anal-
yses were carried out as described previously (Izquierdo and Valca´rcel,
2007b). Control experiments with different input amounts of RNA indicated that
the amplification was quantitative under these conditions (Izquierdo et al., 2005). The
oligonucleotide primers used were TRAIL.sense (5-ATGATTTTGAGAACCTCT-
GAGGAAA-3) and TRAIL.antisense (5-TTTGTTTGTCGTTC-TTTGTGTTTTC-3)
for human TRAIL gene; caspase-2.sense (5-ATGGACGAAGCGGAT-CGG-3) and
caspase-2.antisense (5-CCCTGGCCTTAT-GATGTT-3) for human caspase-2 gene.
The primers PT1 and PT2, -actin.sense and -actin.antisense, as well as Fas
exon5.sense and Fas exon7.antisense used to analyze alternatively spliced products
from wild type/mutant Fas minigene, endogenous -actin and Fas genes, respec-
tively, were described previously (Fo¨rch et al., 2000; Izquierdo and Valca´rcel, 2007b).
siRNA Duplex Preparation and Transfection of siRNAs
The sequences of the 21-nt siRNA oligonucleotides used for targeting TIA-1,
TIAR, and PTB were synthesized and annealed as described previously
(Elbashir et al., 2001; Izquierdo et al., 2005). HeLa cells were transfected at 30%
confluence with 2 g of small interfering RNAs (siRNAs) by using Lipofectin
(Invitrogen). Cells were incubated for 72 h before protein extract preparation.
RESULTS
U2AF65 Is Cleaved during Apoptosis in Jurkat Cells
Jurkat cells were incubated with the anti-Fas antibody, a
well-established apoptotic agent. After 2 h of treatment, a
fragment of U2AF65 with an apparent molecular mass of 42
kDa was identified by anti-U2AF65 antibody MC3. This
fragment became more prominent 3–4 h after treatment
(Figure 1A, lanes 2–4, identified as U2AF65*). The cleavage
of U2AF65 was inhibited when apoptosis was blocked by
pretreatment for 1 h with the z-VAD-fmk peptide, a broad-
spectrum caspase inhibitor (Figure 1A, lanes 5–7). It is there-
fore very likely that U2AF65 cleavage is a consequence of
Figure 1. U2AF65 cleavage occurs during apo-
ptosis. (A) Jurkat cells in the absence (lanes 1–4) or
in the presence (lanes 5–7) of z-VAD-fmk were
incubated with the anti-Fas antibody. (B) Jurkat
cells were incubated with anti-Fas antibody alone
(lanes 1–4) or with this antibody plus staurospor-
ine (lanes 5–8). (C) HeLa cells were treated with
the indicated apoptotic agents for 16 h. Lane 6,
HeLa cells pretreated with z-VAD-fmk as de-
scribed in A. In A–C, protein extracts were immu-
noblotted with the indicated antibodies. The iden-
tities of molecular mass markers and protein
bands are shown. (D) Protein extracts from HeLa
cells treated as in described in C were harvested to
test caspase-3 or caspase-3-like activity. Where in-
dicated (black bars), 5 M DEVD-fmk was incu-
bated before the addition of the substrate DEVD-
p-NA. Caspase activity was displayed as the
number of nanomoles of p-NA released per hour
per total milligram of protein as calculated from a
standard curve by using free p-NA. The values of
caspase activity are means  SEM for at least two
independent samples.
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apoptosis induction. The cleavage of the well-characterized
caspase-3 and -7 target protein PARP was also determined
as a control marker of caspase activity (Figure 1A, bottom).
In agreement with published data (Earnshaw et al., 1999),
PARP cleavage leads to the appearance of an 85-kDa prod-
uct as early as 2 h after antibody treatment (Figure 1A,
bottom, lanes 2–4). PARP cleavage was inhibited in the
presence of 5 M z-VAD-fmk (Figure 1A, bottom, lanes 5–7).
Together, these results suggest that U2AF65 is cleaved by
caspases during apoptosis. However, U2AF65 cleavage was
less efficient and slightly delayed compared with cleavage of
PARP (Figure 1A, top and bottom, lanes 2–4).
U2AF65 Cleavage Is a General Apoptotic Event
To rule out whether U2AF65 cleavage was restricted to
anti-Fas antibody-mediated apoptosis, cleavage was ana-
lyzed in Jurkat cells treated with anti-Fas antibody alone
(Figure 1B, lanes 1–4); anti-Fas antibody together with a
potent and general kinase inhibitor, staurosporine (Figure
1B, lanes 5–8); or with a strong translational elongation
inhibitor, cycloheximide (data not shown). Both apoptotic
agents increased the efficiency of U2AF65 cleavage (Figure
1B, top, lanes 4 and 7–8; data not shown). The extent of
proteolysis seems to correlate well with the potency of the
apoptotic agent used. To reinforce this point, HeLa cells
were treated for 6 h (data not shown) or 16 h (Figure 1C)
with the following apoptotic agents: anti-Fas antibody, stau-
rosporine, cycloheximide, and UV light. As shown in Figure
1C (lanes 2–5), similar profiles of U2AF65 cleavage were
observed in all cases. PARP cleavage and caspase-3/
caspase-3–like activity were used as control markers of ap-
optosis (Figure 1C, middle, lanes 2–5; and D, white bars).
-Tubulin was used both as a loading control and as a
protein resistant to apoptotic stimuli (Figure 1C, bottom).
Inhibition of U2AF65 and PARP cleavage and caspase-3/
caspase-3–like activity were observed when the HeLa cells
were preincubated with z-VAD-fmk and DEVD-fmk pep-
tides, respectively (Figure 1C, top and middle, lanes 6; and
D, black bars). These data confirm that U2AF65 cleavage is a
general molecular event during apoptosis.
Subcellular Localization of U2AF65 during Apoptosis
In nonapoptotic cells, U2AF65 is localized mainly in the
nucleus, with accumulation in speckles (Figure 2A, top im-
ages; Gama-Carvalho et al., 1997). However, the U2AF65-
related fluorescence was found in the cytoplasm of apoptotic
HeLa cells treated with staurosporine or irradiated with UV
light (Figure 2A, middle and bottom), suggesting changes in
the subcellular distribution of U2AF65 and/or the resulting
U2AF65 proteolytic fragments. To confirm this notion, the
distribution pattern of the U2AF65 proteolytic fragment (42
kDa) generated upon apoptosis induction and recognized by
monoclonal anti-U2AF65 antibody MC3 was investigated.
This fragment was localized mainly in the cytoplasmic frac-
tion (Figure 2B, top, lanes 4–9). Apoptosis did not change
the subcellular distribution of the 85-kDa proteolytic frag-
ment of PARP with respect to the native protein (Figure 2B,
bottom). However, apoptosis induction by UV light irradi-
ation alters nuclear pore and transport systems (Buendia et
al., 1999) as shown by the distribution of -tubulin (Figure
2B, bottom, lane 8).
In Vitro Cleavage of U2AF65 by Group I or III Caspases
To prove that caspases are directly involved in U2AF65
cleavage and to identify the responsible caspases, in vitro
cleavage assays were carried out. TIA-1 and U2AF65-
Figure 2. Subcellular localization of U2AF65
in apoptotic cells. (A) HeLa cells were mock
treated or treated with staurosporine or irra-
diated with UV light and then stained with
anti-U2AF65 mAb MC3. From left to right,
images show cells examined using Nomarski
method (Nomarski), stained with Hoechst
through a 4,6-diamidino-2-phenylindole (DAPI)
filter (DNA), or stained with anti-U2AF65 anti-
body and examined with a tetramethylrhodam-
ine B isothiocyanate filter (U2AF65). The two
right-hand images (Merge and Detail) are the
sum of DNA and U2AF65 images as well as
detailed images. In DNA, U2AF65 and Merge
images, bars represent 30 m. In detailed im-
ages, bars represents represent 5 m. (B) Frac-
tions containing either total protein (T), nuclei
(N), or postnuclear supernatant (C) from HeLa
cells mock treated (lanes 1–3), treated with stau-
rosporine (lanes 4–6), or irradiated with UV
light (lanes 7–9) were analyzed with the indi-
cated antibodies. The migrations of molecular
mass markers and protein bands are indicated.
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enriched nuclear extracts (Dignam et al., 1983) were incu-
bated with recombinant caspases from group I (caspase-1,
-4, and -5), group II (caspase-2, -8, -9, and -10), or group III
(caspase-3, -6, and -7) (Figure 3). The cleavage patterns
showed the appearance of the 42-kDa proteolytic fragment
of U2AF65 in the samples containing caspase-1, -3, -4, -5, and
-7 (Figure 3A, lanes 3 and 5–7; and B, lane 4). Nevertheless,
TIA-1—used as a specificity control—was only cleaved by
caspase-4 (Figure 3A, middle, lane 6). PARP cleavage was
used as a positive control of caspase activity (Figure 3, A and
B, bottom, lanes 3–7). These findings demonstrate that group
I or III caspases mainly cleave U2AF65 in vitro, giving rise to
the same proteolytic product obtained in Jurkat and HeLa
cells after apoptosis induction.
Van Damme et al. (2005) suggested that the aspartic acid128
of U2AF65 protein, in the MTPD sequence context (Figure
3C), defines a noncanonical target site for caspases (Van
Damme et al., 2005). The size of the U2AF65 proteolytic
fragment recognized by the monoclonal antibody (mAb)
MC3 (Figure 3C) and the high degree of conservation of this
aspartate residue in the animal kingdom from Homo sapiens
to Drosophila melanogaster (Supplemental Figure 1) are con-
sistent with this prediction. To test this possibility, in vitro
cleavage reactions were carried out using 35S-labeled
U2AF65 and recombinant caspases. An efficient cleavage
was obtained on incubation with caspases-1, -4, -5, and -7
(Figure 3, D and E, lanes 3 and 5). This cleavage decreased
markedly when an U2AF65 mutant, in which the aspar-
tate128 was substituted by alanine (D128A), was used (Figure
3, D and E, lanes 7 and 9). The less efficient cleavage ob-
served with caspase-3 or -6 (Figure 3, D and E, lanes 4) was
blocked when the D128A mutant protein was used as well
(Figure 3, D and E, lanes 8). Efficient cleavage of 35S-labeled
TIA-1 isoform b by caspase-4 was used as a specificity
control (Figure 3F, lane 4). As a whole, these results confirm
that aspartate128 is the caspase target site on human U2AF65
protein. An intriguing observation was that U2AF65 cleav-
age by caspase-6 is different in HeLa cells compared with
reticulocyte lysates (compare Figure 3, B and E). This fact
was also observed with TIA-1 cleavage by caspase-4 (Figure
3, A and F). The results suggest that the recombinant
caspases used in our study are more effective at cleaving
proteins expressed in reticulocyte lysates than proteins from
HeLa nuclear extracts. The simplest explanations are that the
relative quantities of target proteins for caspases are differ-
ent, and/or there are additional requirements for optimal
caspase activity that vary between sample sources.
The U2AF65 N-Terminal Fragment Seems to Be Localized
in Nuclear Bodies
The above-mentioned results suggest that U2AF65 cleavage
by caspases gives rise to an N-terminal fragment (U2AF65-
127) containing the arginine and serine (RS)-rich domain,
which functions as a nuclear localization signal (amino acids
aa23-aa63) and the U2AF35 binding site (Figure 3C; Gama-
Carvalho et al., 1997; Gama-Carvalho et al., 2001), and a
C-terminal fragment (U2AF65-128) that contains the three
RRMs (Figure 3C). Therefore, it seems likely that resulting
proteolytic fragments should have a different subcellular
distribution (Gama-Carvalho et al., 1997, 2001). To test this
hypothesis, GFP was fused to the N termini of both frag-
ments, and HeLa cells were transfected with the correspond-
ing constructs (Figure 4). GFP alone had a cytoplasmic and
nuclear localization (Figure 4, first row), whereas GFP-
U2AF65 localized mainly to speckles in the nucleus (Figure
4, second row). However, GFP-U2AF65-127 fusion protein
showed a heterogeneous distribution in nuclear bodies with
nucleolus-like pattern and diffuse fluorescence around the
cytoplasm (Figure 4, third row). The GFP-U2AF65-128 fu-
sion protein was mainly found in the cytoplasm (Figure 4,
fourth row). The distribution patterns of the GFP-tagged
U2AF65 fragments were further investigated and confirmed
by subcellular fractionation (data not shown). These find-
ings were confirmed by performing localization studies in
HeLa cells transfected with plasmids expressing either GFP-
U2AF65 or U2AF65-GFP fusion proteins on apoptosis induc-
tion. In nonapoptotic cells, GFP-U2AF65 or U2AF65-GFP
recombinant proteins were localized in nuclear speckles
(Supplemental Figure 2, first and fourth rows). However, in
apoptotic cells treated with staurosporine or irradiated
Figure 3. U2AF65 is mainly cleaved by
group I or III caspases at the aspartate128. (A
and B) HeLa nuclear extracts were incubated
with either no additional agents (lane 1),
buffer alone (lane 2), or buffer plus each of the
caspases (lanes 3–7) and analyzed by Western
blotting using the antibodies against the indi-
cated proteins. (C) Schematic structure of hu-
man U2AF65 protein. The amino acid se-
quence around the caspase cleavage site is
shown in single-letter symbol of amino acids.
The RS-rich sequence, U2AF35 binding site
and RRM functional domains are indicated by
open boxes, and the amino acid number
is shown. The epitope recognized by anti-
U2AF65 mAb MC3 is indicated. (D and E)
35S-labeled U2AF65 wt (lanes 1–5) or mutant
D128A (lanes 6–10) was incubated with either
none (lanes 1 and 10), buffer alone (lanes 2), or
buffer plus each of the caspases indicated
(lanes 3–5 and 7–9). (F) 35S-labeled TIA-1b was
incubated with each of the caspases (lanes
1–10) as indicated. In panels, the positions of
U2AF65, TIA-1 or PARP and molecular mass
markers are shown.
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with UV light, GFP-related fluorescence from GFP-tagged
U2AF65 fragments was preferentially detected in cell clus-
ters (N-terminal fragment) (Supplemental Figure 2, second
and third rows) and cytoplasm (C-terminal fragment) (Sup-
plemental Figure 2, fifth and sixth rows).
Functional Impact of the U2AF65 Proteolytic Fragments
on Fas Splicing
The major function of U2AF65 is the recognition of the 3ss
of pre-mRNAs during RNA splicing taking place in the
nucleus (Zamore et al., 1992). Because the U2AF65 fragments
generated during apoptosis were relocalized in the nucleo-
lus and cytoplasm, it was deemed relevant to study their
effects on U2AF65-dependent splicing by using a human
minigene. This minigene comprises human Fas genomic
sequences from exons 5–7 (Fo¨rch et al., 2000). The features of
consensus sequences at the 3ss of introns 5 and 6 are very
interesting from a mechanistic viewpoint because intron 5
3ss can be defined as weak, and thus highly U2AF65 de-
pendent, whereas intron 6 3ss can be defined as strong, and
subsequently less U2AF65 dependent (Izquierdo et al., 2005;
Pacheco et al., 2006a). U2AF65 overexpression (Figure 5A,
lane 3) versus GFP (Figure 5A, lane 2) promoted partial
skipping of exon 6 in Jurkat cells (Figure 5B, lane 3, and C).
This was evident also when the N-terminal fragment was
overexpressed (Figure 5, A and B, lanes 4; and C). Given the
fact that overexpression of U2AF65 leads by itself to the
appearance of a truncated fragment that comigrates with
U2AF65-127 (Figure 5A, lane 3), the simplest interpretation
of these results is that the effect observed is due to this
truncated fragment. In contrast, overexpression of the
U2AF65 C-terminal fragment (Figure 5A, lane 5) did not
significantly affect Fas splicing (Figure 5B, lane 5; and C),
indicating that the U2AF65 N-terminal fragment down-reg-
ulates exon 6 inclusion. This effect could be explained by
assuming that overexpression of the U2AF65 N-terminal
fragment sequesters endogenous U2AF35 and therefore
causes dilution of functional endogenous U2AF65-U2AF35
heterodimer, which will not favor the selection of the weak
3ss of intron 5. If this were true, U2AF35 transfection should
have similar consequences. As expected, U2AF35 overex-
pression (Figure 5A, lane 6) promoted significant exon 6
skipping (Figure 5B, lane 6; and C). This idea was further
supported in that overexpression of both U2AF subunits
(Figure 5A, lane 7) can partially rescue exon 6 inclusion
(Figure 5B, lane 7; and C). In the same vein, overexpression
of the U2AF65 N-terminal fragment compared with U2AF35
(Figure 5A, lane 8) promotes inclusion of Fas exon 6 (Figure
5B, lane 8; and C). Similar results were also obtained using
HeLa cells (data not shown). Together, these findings sup-
port the idea of dominant-negative behavior of the U2AF65
N-terminal fragment, suggesting that apoptosis-associated
caspase activity disrupts U2AF65 interaction with U2AF35,
which might contribute to down-regulation of Fas exon 6
splicing.
To provide more evidence of the functional relevance of
U2AF65 cleavage for Fas alternative splicing in a cellular
context, Jurkat cells were incubated with the apoptosis in-
ducers anti-Fas antibody and cycloheximide for the indi-
cated times (0–3 h), and endogenous Fas exon 6 splicing
event was examined (Figure 5, D and E). Cell extracts were
processed by immunoblotting with antibodies against
U2AF65, PARP, and -tubulin proteins (Figure 5D) to con-
firm apoptosis induction and U2AF65 cleavage. Addition-
ally, cytoplasmic RNAs were analyzed by RT-PCR (Figure
5E) to determine the alternatively spliced products of the Fas
gene. The results show that U2AF65 proteolysis during early
apoptosis induction for 3 h favors Fas exon 6 skipping
(Figure 5E). In the same vein, the consequences of the com-
plete U2AF65 cleavage on splicing events of endogenous
pre-mRNAs during apoptosis were also investigated. In
vivo splicing events of proapoptotic (Fas and caspase-2),
anti-apoptotic (tumor necrosis factor-related apoptosis-in-
ducing ligand [TRAIL]), and control (-actin) pre-mRNAs
were tested. Jurkat cells treated with anti-Fas antibody to-
gether with staurosporine for 4 h showed that full endoge-
nous U2AF65 proteolysis occurred (Supplemental Figure
3A). In these conditions, the results indicated that the events
of alternative splicing were affected differently by apoptosis
than the events of constitutive splicing. This affirmation is
based on the fact that inhibition of all alternative splicing
events examined was observed, whereas constitutive splic-
Figure 4. Subcellular distribution of the
U2AF65 N- and C-terminal fragments as GFP-
tagged fusions. HeLa cells were transfected
with plasmids expressing GFP (top images),
GFP-fused with either U2AF65 (top mid-
dle images), the U2AF65 N-terminal fragment
(SR domain) (lower middle images), or the
U2AF65 C-terminal fragment (RRM123) (bot-
tom images). The left-hand images show cells
examined using Nomarski method. Fluores-
cence from GFP was observed using a fluores-
cein filter. To visualize nuclei, DNA was
stained with Hoechst and examined using a
DAPI filter. The two right-hand columns are
merged and detailed images, respectively. In
DNA, GFP-fusions and Merge images, bars
represent 30 m. In detailed images, bars rep-
resent 5 m.
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ing corresponding to the -actin exons 5 and 6 seemed to be
only partially affected (Supplemental Figure 3C), although
in the putative contribution of the half-life of -actin mRNA
cannot be ruled out. In contrast, the “disappearance” of
unspliced products might be a consequence of experimental
approach used (semiquantitative RT-PCR), which does not
allow amplification of unspliced endogenous mRNA precur-
sors given that these are too large. To directly address this,
a mutant Fas minigene reporter—identified as Fas I6,
which contains a partial deletion (1000 nt) of intron 6—was
used to visualize whether Fas pre-mRNA was spliced or
unspliced in mock cells and treated Jurkat cells with apo-
ptotic agents (Supplemental Figure 3D). The results showed
that in nonapoptotic Jurkat cells, the Fas I6 pre-mRNA was
spliced with strong exon 6 skipping, whereas the Fas pre-
mRNA was unspliced on apoptosis induction (Supplemen-
tal Figure 3D). The accumulation of unspliced Fas pre-
mRNA correlates well with the reduction of intact U2AF65
and the appearance of proteolyzed U2AF65. However, the
constitutive splicing of endogenous -actin pre-mRNA was
Figure 5. U2AF65 cleavage modulates endogenous Fas alternative splicing in Jurkat cells. (A) Protein extracts from untransfected and
transfected Jurkat cells with the plasmids indicated were analyzed by Western blotting using anti-GFP, anti-U2AF65, or -tubulin antibodies.
Ectopic GFP expression from GFP-tagged U2AF65 plasmids and its derivatives is shown in the top panel. Endogenous U2AF65 and -tubulin
expression and equal loading are shown in the bottom panels. (B) Cytoplasmic RNAs from Jurkat cells processed in A were analyzed by
RT-PCR using primers PT1 and PT2. (C) The values of ratios between 5–7 and 5-6-7 amplification products are means  SEM for at least two
to three independent experiments. These values were expressed relative to GFP expression (B, lane 2), whose value was fixed arbitrarily to
1. (D and E) Jurkat cells were incubated with the apoptosis-inducers anti-Fas antibody (500 ng/ml) and cycloheximide (10 g/ml) for the
indicated times (0–3 h). (D) Total cell extracts were analyzed by immunoblotting using antibodies against U2AF65, PARP, and -tubulin. (E)
Cytoplasmic RNAs were isolated from apoptotic Jurkat cells in D and analyzed by RT-PCR. The products of amplification were separated
by agarose-gel electrophoresis. The values of ratios between 5-6-7 and 5–7 amplification products are means  SEM for at least two
independent experiments. These values were normalized relative to lane 1, whose value was fixed arbitrarily to 1. In D and E, positions of
molecular mass markers, protein bands and predicted alternatively spliced products are indicated. (F) The siRNA-mediated down-expression
of PTB promotes the U2AF65 cleavage. Western blot analysis of HeLa cell lysates (5 g [1:5] or 25 g, lanes 1 and 2–5, respectively) prepared
72 h after transfection with siRNAs against GFP (lanes 1 and 2), TIA-1 (lane 3), TIAR (lane 4), and PTB (lane 5). The blot was probed with
antibodies against PTB, U2AF65, TIA-1, TIAR, and -tubulin proteins, as indicated. Molecular weight markers and the identities of protein
bands are indicated.
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partially affected in the same experimental conditions (Sup-
plemental Figure 3D). Together, these observations are con-
sistent with the idea that U2AF65 cleavage might represent
an epigenetic event that induces drastic changes in the reg-
ulation of gene expression on apoptosis induction. The ob-
servations also reinforce the idea that proteolytic cleavage of
U2AF65 may represent a potential mechanism for increasing
alternative splicing relative to constitutive splicing during
early apoptosis, through the imbalance between free and
heterodimeric forms of U2snRNP auxiliary factors.
PTB siRNA-mediated Knockdown Promotes
U2AF65 Cleavage
Finally, to illustrate whether cleaved U2AF65 is present in
human cells under normal growing conditions, we screened
several well-established human cell lines (HeLa, Jurkat,
Daudi, 293, Rh 30, A375, T98G, HCT-116, and Hep-G2). The
results indicate that cleaved U2AF65 is not found in cell lines
tested (data not shown). However, HeLa cells transfected
with a double-stranded siRNA against PTB showed a sig-
nificant reduction in the relative U2AF65 level (Figure 5F,
lane 5). Interestingly, this reduction occurred in parallel with
the appearance of a 42-kDa fragment of U2AF65 (indicated
as U2AF65*) in this cell extract (Figure 5F, lane 5). Normal
levels of intact U2AF65 protein were observed in HeLa cells
treated with siRNAs against TIA-1 or TIAR in the same
depletion conditions (80%) (Figure 5F, lanes 3 and 4). The
levels of -tubulin were used as loading control (Figure 5F,
lanes 1–5). Given that PTB-siRNA transfection led to the
altered morphology in which a significant number of the
cells were round and lost adherence (data not shown; He et
al., 2007), the appearance of the 42-kDa proteolytic fragment
of U2AF65 was considered a consequence of genotoxic re-
sponse/stress to PTB depletion.
DISCUSSION
We report here that human U2AF65 cleavage is a general
apoptotic event dependent on groups I or III caspase activ-
ity, generating two U2AF65 fragments with a prevalent sub-
cellular distribution in nuclear bodies that seem to be
nucleoli (N-terminal fragment) and cytoplasm (C-terminal
fragment). The relevant biological consequences for the reg-
ulation of Fas alternative splicing are derived from this
observation.
Cellular Consequences of U2AF65 Cleavage by Caspases
The caspase recognition of Asp128 in U2AF65 is preceded by
a noncanonical caspase target sequence containing the
amino acids MTPD. This sequence represents a nonconven-
tional cleavage site for caspases from groups I—with con-
ventional cleavage site including WEHD and (W/L)EHD—
and III—with conventional cleavage site including DEVD
and VEHD (Lavrik et al., 2005). However, the sequence
together with its context is highly conserved from Drosophila
to human (Supplemental Figure 1), implying that U2AF65
cleavage during apoptosis may play an important physio-
logical role in a large group of animals. In addition, this
finding may suggest that not only the primary sequence but
also the conformation of U2AF65 may contribute to caspase
recognition. Our results also suggest that the effector
caspases from groups I and III are the caspases that specif-
ically cleave this target protein during apoptosis.
U2AF65 is a protein that resides in the nucleus, mainly in
speckles (Gama-Carvalho et al., 1997), which are nuclear
bodies where transcription and splicing factors accumulate.
The results presented suggest that after apoptosis induction
and caspase activation, U2AF65 is cleaved into two parts:
the N-terminal fragment, containing the R/S domain and
U2AF35 binding motif; and the C-terminal fragment, which
contains the three RRMs. By transfecting HeLa cells with the
GFP/U2AF65-RS-35 and GFP/U2AF65-RRM1, -2 and -3 de-
rivative constructs, which produce GFP-fused to N-/C-ter-
minal fragments of U2AF65, we have demonstrated that
these U2AF65 fragments seem to be localized in the nucle-
olus and cytoplasm, even when the localization studies are
performed on induction of apoptosis. Subcellular redistribu-
tion of U2AF65 fragments may be attributed to several phe-
nomena occurring during apoptosis. First, the N-terminal
region of U2AF65 (up to RRM1) containing a stretch of basic
amino acids followed by RS dipeptides and a putative bi-
partite nuclear localization signal (NLS) (Gama-Carvalho et
al., 2001) is separated from the C-terminal region (RRM1, -2,
and -3). Therefore, the RS domain on U2AF65 can act as an
NLS, and it is sufficient to direct a heterologous protein to
the nucleus. Moreover, the fragment containing the RS-rich
domain is sufficient to relocalize a heterologous protein to
the nucleolus. Several experimental results suggest that RS
domains can interact with both single- and double-strand
RNAs such as intron/exon RNA sequences or the ribosomal
RNAs localized to the nucleolus (Shen and Green, 2006).
Given that GFP-U2AF65-127 fusion protein is small it prob-
ably enters the nucleolus by diffusion and is retained by
nonspecific binding of the RS domain to rRNA (Gama-
Carvalho et al., 2001; Shen and Green, 2006). Second, with
regard to the cytoplasmic localization of this protein, mod-
ification of the nuclear pore complex occurs during apopto-
sis. Several reports have suggested that the activation of
caspases during apoptosis increases nuclear pore permeabil-
ity by cleaving components of both the nuclear pore and the
nuclear transport system (Buendia et al., 1999; Ferrando-
May, 2005). These modifications result in leakage of proteins
restricted to the nucleus into the cytoplasm and vice versa
(Figure 2B; see -tubulin in lane 8). Third, inhibition of
transcription during apoptosis may partly contribute to the
relocalization of U2AF65 fragments, because inhibition of
cellular transcription by actinomycin D induces the partial
redistribution of U2AF65 to the cytoplasm (Gama-Carvalho
et al., 1997).
Early recognition of the 3 ends of introns is achieved in
higher eukaryotes by the U2AF, which is made up of a large
subunit (U2AF65) and a small subunit (U2AF35) that inter-
act to form a stable heterodimer. U2AF65 binds to the poly-
pyrimidine tract upstream from the 3 splice site and pro-
motes U2 snRNP binding to the pre-mRNA; therefore, it is
an essential factor for splicing. When apoptosis is induced
and U2AF65 is cleaved, the nuclear functions of complete
U2AF65, such as the control of Fas alternative splicing, are
compromised. Our findings (Figure 5, A–C) suggest that
apoptosis-associated caspase activity disrupts U2AF65 func-
tional interaction with U2AF35, which might contribute to
splicing modulation. This observation could be explained by
assuming that the U2AF65 N-terminal fragment—the
U2AF65 C-terminal fragment generated by caspases was
mainly localized in the cytoplasm and did not affect
Fas splicing—promotes dilution of functional endogenous
U2AF65-U2AF35 heterodimer, which will not favor the se-
lection of the 3 splice sites. These findings agree with pre-
vious results that strongly suggest that U2AF regulates the
splicing of a subset of endogenous pre-mRNAs containing
alternative 3ss associated with PTs of different strengths
(Pacheco et al., 2006a,b). Therefore, it is tempting to specu-
late that a fine-tuning regulation is operating to control the
amount of each factor to compensate the cellular balance of
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free U2AF65 or U2AF35 and U2AF65-U2AF35 heterodimer.
Additionally, U2AF65 has been implicated in the regulation
of 3 end processing (Millevoi et al., 2006; Danckwardt et al.,
2007). In this regard, we speculate that the coupling of
splicing and 3 end processing of mammalian pre-mRNAs
should be altered as well. A very striking common feature of
the apoptosis-targeted proteins is the presence of an RNA
binding motif, which is likely to play a role in RNA splicing
(Fischer et al., 2003). The physiological significance of such
selective changes on RNA-binding protein family members
and/or spliceosome machinery-associated factors during
apoptosis remains unknown. It will certainly be a challenge
to understand a process as complex as splicing/3 end pro-
cessing in the context of apoptosis, where multiple factors
are processed and may be functionally modified. In contrast,
U2AF65 cleavage and the resulting fragments could also
have functional consequences for the metabolism of the
cytoplasmic mRNAs. In our experiments, the U2AF65 N-
and C-terminal portions had no effect on the translational
activity of the -galactosidase reporter mRNA (data not
shown). However, U2AF65 cleavage during apoptosis may
modulate translation/stability of particular species of mR-
NAs given that a role for U2AF65 in the cytoplasmic metab-
olism of specific mRNAs has been reported (Gama-Carvalho
et al., 2006).
Fas Splicing Regulation during Apoptosis
Fas is a quintessential death receptor, and cells undergo
apoptosis on ligation. Alternative Fas pre-mRNA splicing
can regulate the sensitivity of Fas-expressing cells to Fas-
induced apoptosis. The protein isoform of the mRNA lack-
ing exon 6 encodes the soluble form of the receptor able
to inhibit Fas signaling (Cheng et al., 1994). This process is
regulated in a number of physiological situations, including
activation-mediated T cell death and autoimmune lympho-
proliferative disorders (Bidere et al., 2006). However, other
studies have shown that soluble human Fas protein can
induce death of transformed cells by “reverse” apoptotic
signaling via transmembrane Fas ligand (Proussakova et al.,
2003). Its cytotoxicity seems to be linked to the oligomeriza-
tion of soluble Fas antigen (Proussakova et al., 2003). Thus,
several questions need to be answered about this issue in
futures studies: What is the role of altered splicing of Fas
protein? Would this inactivate Fas production? Is this a
protective response, that is, could it prevent apoptosis, or is
it more likely to accelerate cell death by apoptosis? Greater
understanding of the mechanisms that regulate function and
expression of the Fas receptor as well as its mediation in
other processes, including cell proliferation or differentiation
and their signaling pathways, will provide relevant insight
into the regulatory circuits of apoptosis.
Apoptosis is a crucial event in many biological processes
(Earnshaw et al., 1999; Krammer, 2000; Adams, 2003). The
essential splicing factor U2AF65 participates in spliceosome
recruitment and regulation of constitutive and alternative
splicing. The present study provides important new infor-
mation on cleavage of U2AF65 during apoptosis. Cleaved
U2AF65 may influence the progression of apoptosis, partic-
ularly through effects on alternative splicing control. Ac-
cording to the current understanding of apoptosis, caspase
activation can be considered the point of no return, that is,
the cell seems to be definitively committed to die. However,
situations might arise in which caspases are activated but
cells do not enter apoptosis due to overexpression of inhib-
itors of apoptosis and/or survival factors. It is feasible that
regulation of splicing under these conditions influences the
apoptotic process in a long-term manner, as a second wave,
by producing inhibitors or activators of survival. There are
many examples of alternatively spliced factors with pro- or
anti-apoptotic activities (for review, see Schwerk and
Schulze-Osthoff, 2005). Why should a cell programmed to
die modify its RNA splicing metabolism? The regulation of
apoptosis might require a sudden response, which would be
obtained by posttranscriptional RNA processing rather than
by the biosynthesis of RNA. For example, it might be im-
portant to remove ribonucleoprotein complexes, perhaps to
quickly mount a comprehensive assault on most of the cell’s
vital systems and to allow hierarchical and irreversible de-
struction of the cell (Keene and Tenenbaum, 2002; Mata et al.,
2005; Moore, 2005; Leung and Sharp, 2006; Prasanth and
Spector, 2007). In summary, U2AF65 undergoes proteolytic
processing by caspases. This processing is associated with a
reduction in U2AF65 expression, the formation of two dis-
crete cleavage fragments, and alterations in U2AF65 splicing
activity. As such, this caspase-mediated processing may rep-
resent an additional mechanism to modulate U2AF65 func-
tionality and Fas alternative splicing under apoptotic condi-
tions.
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